読み込み中
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
前日終値
$5.95
+$0.22 · +3.84%
日中の時刻はETです。市場データは遅延する場合があります。
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
日中レンジ
現在 $5.95
52週レンジ
現在 $5.95
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
73
割安
センチメント
56
まちまち
リスク
52
やや高いリスク
モメンタム
36
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Orchestra BioMed Holdings, Inc. operates as an innovative company in the biomedical sector. Its leading product candidates are BackBeat Cardiac Neuromodulation Therapy (CNT), designed to manage hypertension, and the Virtue Sirolimus AngioInfusion Balloon (SAB), aimed at treating atherosclerotic artery disease. The company's offerings also encompass FreeHold retractors, which are solutions for minimally invasive surgical procedures. Orchestra BioMed has formed key alliances to advance its products: a strategic collaboration with Medtronic focuses on developing and commercializing BackBeat CNT for pacemaker-indicated patients suffering from hypertension. Additionally, a partnership with Terumo Corporation is dedicated to the development and market introduction of Virtue SAB for artery disease. The company's headquarters are located in New Hope, Pennsylvania.
日中レンジ
現在 $5.95
52週レンジ
現在 $5.95
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 3348.2万 USD | 263.8万 USD | 276万 USD | 353.3万 USD | −78.2万 USD |
| 売上原価 | 19万 USD | 20.4万 USD | 18.6万 USD | 32.2万 USD | 19.9万 USD |
| 粗利益 | 3329.2万 USD | 243.4万 USD | 257.4万 USD | 321.1万 USD | −98.1万 USD |
| 研究開発 | 5818.5万 USD | 4280.4万 USD | 3382.2万 USD | 2194.5万 USD | 1289万 USD |
| 販売・一般管理 | 2691.4万 USD | 2393.1万 USD | 2025.8万 USD | 1392.3万 USD | 792.8万 USD |
| 営業費用 | 8509.9万 USD | 6673.5万 USD | 5408万 USD | 3586.8万 USD | 2081.8万 USD |
| 受取利息 | — | 335.6万 USD | 384.9万 USD | 5万 USD | — |
| 支払利息 | 114.8万 USD | — | — | — | 92.7万 USD |
| 減価償却費と償却費 | 32.7万 USD | 30.8万 USD | 28.7万 USD | 22.2万 USD | 18.1万 USD |
| 営業利益 | −5180.7万 USD | −6430.1万 USD | −5150.6万 USD | −3265.7万 USD | −2179.9万 USD |
| 純利益 | −5270.1万 USD | −6102.4万 USD | −4912万 USD | −3360.8万 USD | −2301.4万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$10.75
上昇余地（80.67%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI740.91万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM574.66万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF251.31万0.00%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO213.64万0.02%139.17億 USD0.24%$356.78+0.94%
Schwab U.S. Small-Cap ETFSCHA132.9万0.01%218.24億 USD0.03%$32.79+0.40%
Simplify Propel Opportunities ETFSURI130.54万1.72%7606.44万 USD2.82%$17.06-0.14%
Vanguard Russell 2000 ETFVTWO115.78万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC71.45万0.05%13.17億 USD0.60%$183+0.11%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHASimplify Propel Opportunities ETFSURIVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
